08
May

08:00 AM EST

Medicinal Chemistry

Name: Medicinal Chemistry Strategy Meeting East Coast 2025 (Boston)
Start: 2025-05-08T08:00
End: 2025-05-08T18:00
Location: Crowne Plaza, London Docklands

Strategy Meeting East Coast USA 2025

Reinvigorating Productivity in Pharma Biotech Through Advanced Technologies and Innovative Techniques that Interrogate Activity and Mechanisms

Le Meridien Cambridge Boston

A MEETING EXPERIENCE UNLIKE ANY OTHER

Fresh Medicinal Chemistry Insights

Tired of the same conference experience? Real discussions and genuine networking are often promised, but not always delivered. Proventa International’s R&D Strategy Meetings are designed to avoid the pitfalls of a typical conference, by providing the right environment to make those important connections through interactive roundtable discussions, exclusive networking and keynote panel debates. Join Medicinal Chemistry professionals from across the East Coast, in Boston MA, to discover new insights and take your company’s mission to the next level.

What makes our strategy meetings unique?

Roundtable Discussions

Intimate discussions led by renowned industry experts. Have your voice heard and debate alongside like-minded life science executives.

Unrivalled Networking

With senior delegation from big pharma and innovative biotech from across the East Coast, you can network with peers from different locations, all in one place.

Personalised Agenda

Choose the topics that matter to you. Reserve your place at the roundtable discussions and ensure your whole day delivers the insights you need to hear.

Solutions to your Problems

We’ve partnered with the best solution providers to solve your biggest challenges. Engage in pre-arranged, private meetings to address your specific needs and find a tangible solution.

Industry Researched Topics

We guarantee our agenda is up-to-date and mission critical because its designed by you. We speak to our extended network of senior decision makers to ensure the most important topics are discussed.

Senior Decision Makers

The entire strategy meeting is specifically tailored to the needs and challenges of senior life science professionals. Discover how your peers are dealing with the same challenges as you.

Meet Our Facilitators

Our panel of facilitators play a key role in shaping the agenda for the day. See who will be bringing their expertise to the table at our Medicinal Chemistry strategy meeting.

Aimee Usera

Senior Vice President Drug Discovery Odyssey Therapeutics

Benoit Moreau

Head of Medicinal Chemistry Remix Therapeutics

Claire Elizabeth Smith

Partner SpringTide Ventures

David Sherris

CEO Attivare Therapeutics

Session – Next Generation OV and New Combinational Approaches for Treatment of Solid Tumors 
Dr. Sherris has over 30 years’ experience in translational medicine involving basic research, pharmaceutics and diagnostics.  Dr. Sherris has been a successful serial entrepreneur developing biotechnology companies from the ground up, devising corporate strategy, enacting programs and carrying companies through funding and acquisition.  Dr. Sherris prides himself as a “roll up your sleeves” CEO, entrepreneur, business development officer, drug developer and scientist, not simply a delegator. Dr. Sherris has worked with venture capital companies where he has both advised and raised finances for biotech companies.  Dr. Sherris has been employed by pharmaceutical and biotechnology companies to manage external (academic groups and contract research organizations) and internal (directly manage, augment and expand internal scientific programs) research and development. Dr. Sherris has been a frequently invited guest speaker at biopharmaceutical business and scientific conferences, a published author and holder of patents in a wide range of therapeutic areas including oncology, ophthalmology, dermatology, neurology, gene therapy and infectious disease.  Dr. Sherris has held positions of increasing responsibility in public and private companies. Dr. Sherris has developed drugs from the bench to the clinic, partnered technologies to pharmaceutical companies and raised capital for companies at the triple digit million dollar levels.

Diane Joseph-McCarthy

Executive Director, Bioengineering Technology & Entrepreneurship Center Boston University

Dr. David Gosalvez

Chief Strategy Officer Revvity Signals Software

Dr. Tao Guo

SVP and Head WuXi AppTec

Govinda Bhisetti

Vice President and Head of Computational Chemistry Cellarity

Hajnalka Hartl

Head of Chemistry Orogen Therapeutics

Hua Xu

Director, Head of Chemical Biology and Proteomics AstraZeneca

Huseyin Mehmet

Executive Director University of Massachusetts Medical School

Huseyin Mehmet is a drug hunter and research scientist with >35 years’ experience in basic and clinical academic research and in pharmaceutical / biotechnology drug discovery. He received his PhD from the Medical Research Council in the UJ and went on to work at University College London, the Imperial Cancer Research Fund (now Cancer Research UK), Cold Spring Harbor Lab, USA and then took a faculty position at Imperial College School of Medicine. There his work focused on cerebral hypoxic ischemic injury in neonates and he was part of the team that developed mild hypothermia for the treatment of birth asphyxia. In 2006 Huseyin left the UK to join Merck and Co, in the USA. He worked in biomarker discovery, target identification and several drug discovery programs up to clinical candidate selection. For the next few years, he took on roles with increasing responsibility in several biotech companies and also consulted for a number of start-up companies working with prominent VC firms (e.g. Atlas Ventures and Versant Ventures). Since 2021, Huseyin has led the New Ventures team in the BRIDGE Innovation and Business Development office at UMass Chan Medical School, where he is responsible for the scientific partnering of intellectual property arising from faculty discoveries.

Jennifer Petter

Founder and Chief Scientific Officer Arrakis Therapeutics

Kelly Barrett

Business Development Professional SAI Life Sciences

Lee Fader

Vice President Congruence Therapeutics

Lu Gong

Head of Bioinformatics and AI Simcere Pharma

Maneesh Pingle

EVP & Head of Discovery Services Sai Life Sciences

Markus Haeberlein

Executive Vice President, Discovery Science Parabilis Medicines

Markus is currently Executive Vice President, Discovery Science at Parabilis Medicines and holds three decades of experience in Drug Discovery and Early Development spanning many disease areas. Most recently, Markus served as Senior Vice President and Head of Research at Alkermes. During his tenure he helped build a strong research engine focused on exceptional molecular design of small molecules and biologics. An example is the discovery of ALKS 2680 for narcolepsy, a potent agonist for the difficult-to-drug Orexin 2 Receptor. Before Alkermes, Markus was Chief Scientific Officer at Proteostasis Therapeutics, a biotech focused on diseases caused by improper protein degradation, folding and trafficking. Prior to that, Markus spent 15 years at AstraZeneca and held roles of increasing scope and responsibility, including leading AstraZeneca’s Global Chemistry Network where he was responsible for the company’s global chemistry strategy and implementation. A key focus of his strategy was the Predictive Chemistry platform utilizing state-of-the-art computational chemistry methods to improve the design of drug molecules. Markus holds a M.Sc. in Physical Chemistry, Biochemistry, Organic Chemistry and a Ph.D. in Physical Chemistry/Computational Chemistry from the Royal Institute of Technology, Sweden

Matthew Lucas

VP of Medical Chemistry Third Harmonic Bio

Michal Preminger

Former Head of Innovation, East North America Johnson & Johnson Innovation

Nicolas Triballeau

Ph.D. Director of Small Molecule Drug Discovery Revvity Signals

Rich Heidebrecht

Vice President of Research and Development Glycologix

Rocky Goldsmith

Chief Innovation Scientist / Co-Founder Congruence Therapeutics

Samantha Jeschonek Ph.D.

Sr. Product Manager Data Analytics Revvity Signals

Shankar Venkatraman

Executive Director, Chemistry IFM Therapeutics

Over his 20+ year industrial career Shankar Venkatraman has invented and progressed multiple compounds through discovery and into clinical development. He has focused on discovering first-in-class small molecule modulators of new biological pathways, closely integrating medicinal chemistry, pharmacology, and safety to enter clinical trials with these novel entities. Before joining IFM Therapeutics, LLC, Shankar was a Director of Chemistry at Vitae Pharmaceuticals. There he led number of programs including Menin-MLL, resulting in Revumenib (SNDX-5613), currently undergoing multiple clinical trials for ALL/AML with an anticipated NDA filing by the end of 2023. Prior to Vitae, he was a Senior Research Fellow at Merck, where he worked on number of modalities including HIV, neuropathic pain and schizophrenia, and delivered number of clinical candidates. Before joining Merck, Shankar began his medicinal chemistry career at Axys Pharmaceuticals, and worked on cathepsin K, with efforts leading to the identification of Odanacatib. Shankar obtained his Ph.D. in synthetic organic chemistry from University of Minnesota and B.S. in chemistry from University of Bombay. He is co-author/inventor on more than 60 papers and patents.

Stefan Gross

Senior Director and Head of Biochemistry Servier Pharmaceuticals

Stephanie Oestreich

Managing Director Myeloma Investment Fund

OUR AGENDA

See Which Topics Are Discussed at the Strategy Meeting

09:00 – 10:00

Roundtable Tracks

AI/ML
Generative Chemistry in Action: Applications, Challenges, and Breakthroughs

-Govinda Bhisetti
Vice President and Head of Computational Chemistry
Cellarity

Design, Synthesis & Emerging Modalities
Unlocking the Chemical Universe: The Power of DNA-Encoded Libraries in Drug Discovery

-Hajnalka Hartl
Head of Chemistry
Orogen Therapeutics

Chemical Biology, Targeted Protein Degradation And Undruggables
Leveraging Chemical Biology and Proteomics Technologies to Advance Therapeutics for Intractable Targets

-Hua Xu
Director, Head of Chemical Biology and Proteomics
AstraZeneca

Hit Identification / Lead Optimization
Fragment Based Drug Discovery

-Stefan Gross
Senior Director and Head of Biochemistry
Servier Pharmaceuticals

Strategic Partnerships In Drug Discovery
Beyond Algorithms: Forging Strategic Alliances to Power the AI Revolution in Drug Discovery

-Diane Joseph-McCarthy
Executive Director, Bioengineering Technology & Entrepreneurship Center
Boston University

Integrated Drug Discovery
From Hit to Lead: Accelerating Drug Discovery Through Cutting-Edge Chemistry and Innovative Screening Strategies

-Shankar Venkatraman
Executive Director, Chemistry
IFM Therapeutics

11:10 – 12:10

Roundtable Tracks

AI/ML
Emerging Challenges in Machine Learning (ML) -Driven Molecular Property Predictions

Sponsor

Design, Synthesis & Emerging Modalities
Navigating Multi-Dimensional Complexity in Emerging Modalities: How Integrated Platforms Are Transforming PROTACs and ADC Development

-Nicolas Triballeau
Ph.D. Director of Small Molecule Drug Discovery
Revvity Signals

REVVITY SIGNALS

Chemical Biology, Targeted Protein Degradation And Undruggables
Targeted Protein Degradation

-Dr. Tao Guo
SVP and Head
WuXi AppTec

WUXI APPTEC

Hit Identification / Lead Optimization
Lead optimisation of proximity inducing modalities

-Jon Seal
Associate Director of Medicinal Chemistry
SAI Life Sciences

SAI LIFE SCIENCES

Strategic Partnerships In Drug Discovery
Unlocking the Power of Partnership in Drug Discovery

-Kelly Barrett
Business Development Professional
SAI Life Sciences

SAI LIFE SCIENCES

Integrated Drug Discovery
The Data Integration Crisis in Drug Discovery: Why Scientists Spend 60% of Their Time on Data Wrangling Instead of Breakthrough Science

-Samantha Jeschonek Ph.D.
Sr. Product Manager Data Analytics
Revvity Signals

REVVITY SIGNALS

12:15 – 13:15

Roundtable Tracks

AI/ML
Explainable AI (XAI) and ML/AL as assistive intelligence to support rational lead optimization of small molecules

-Rocky Goldsmith
Chief Innovation Scientist / Co-Founder
Congruence Therapeutics

Design, Synthesis & Emerging Modalities
Rational Design Meets Fragmentation: Bridging Structural Biology and Fragment-Based Discovery for Novel Therapeutic Modalities

-Shankar Venkatraman
Executive Director, Chemistry
IFM Therapeutics

Chemical Biology, Targeted Protein Degradation And Undruggables
From PROTACs to RNA-Modulated Degraders: Engineering Novel Therapeutics for Hard-to-Target Proteins

-Benoit Moreau
Head of Medicinal Chemistry
Remix Therapeutics

Hit Identification / Lead Optimization
Drugging Protein:Protein Interactions: Best practices in hit identification and lead optimization of undruggable complexes

-Aimee Usera
Senior Vice President Drug Discovery
Odyssey Therapeutics

Strategic Partnerships In Drug Discovery
Strategic Alliances and Investment Strategies: Fueling the Future of Drug Discovery (Topic TBC)

-Huseyin Mehmet
Executive Director
University of Massachusetts Medical School

Integrated Drug Discovery

14:40 – 15:10

Augmented Discovery: How Revvity Signals’ AI/ML Amplifies Scientific Discovery

David Gosalvez, Chief Strategy Officer, Revvity Signals

15:10 – 16:10

Roundtable Tracks

AI/ML
Fast-Tracking Innovation: Leveraging AI/ML to Accelerate Drug Discovery

-Markus Haeberlein
Executive Vice President, Discovery Science
Parabilis Medicines

Design, Synthesis & Emerging Modalities
Computational & AI-Driven TAA Discovery for Bispecific and Small Molecule ADC Development

-Lu Gong
Head of Bioinformatics and AI
Simcere Pharma

Chemical Biology, Targeted Protein Degradation And Undruggables
Induced Proximity Therapeutics: Drugging Disease Drivers Through Engineered Protein Protein Interaction Enhancers

-Matthew Lucas
VP of Medical Chemistry
Third Harmonic Bio

Hit Identification / Lead Optimization
The Impact of AI and Large Language Models Across the Drug Discovery Pipeline

-Lee Fader
Vice President
Congruence Therapeutics

Strategic Partnerships In Drug Discovery
The Role of Venture Partnerships in Drug Discovery

-Rich Heidebrecht
Vice President of Research and Development
Glycologix

Integrated Drug Discovery
Rewriting the Rules of Therapeutics: The Expanding Frontier of RNA Drug Discovery

-Jennifer Petter
Founder and Chief Scientific Officer
Arrakis Therapeutics

See the full agenda and facilitator line-up Download the strategy meeting brochure for full details

DOWNLOAD THE BROCHURE

Reasons To Attend the Strategy Meeting

Discussions on the advancements in targeted protein degradation and pushing past its boundaries.

Leveraging Artificial Intelligence and Machine Learning in accelerating the development of new drugs

Discuss approaches to further understand the interactions of undruggable targets and different Protein Degraders such as PROTACs, Molecular Glues, etc

Focusing on advancing interrogative techniques to improve the Drug Delivery System/Discovery: Modified mRNA, Nanoparticle-Mediated siRNA, Antibody-Drug Conjugates, and more

Become an official strategy meeting partner Whatever your business needs, we can help. Get in touch for partnering opportunities.

I’D LIKE TO PARTNER

Explore Highlight From The Past Events

Gain valuable insights, discover innovative solutions and connect with industry leaders through snapshots of our most successful gatherings.

Nov
2024

Nov
2023

May
2022

May
2021

Jun
2020

Event Gallery

Press play to hear what your colleagues had to say…

Hotel & Venue

Le Méridien Boston Cambridge

Le Méridien Cambridge-MIT’s elegant guest rooms and suites offer a place of luxurious sanctuary and unmatched comfort. Explore unique programs inspired by the brand’s European heritage. Born in a glamorous era of travel, Le Méridien believes everyone should explore the world in style.

Hotel Details Maps & Direction Parking

Quick Links

Want to find out more?

Find out more details about our Strategy Meetings and other news and events.

Here To Help

Want to know more? Interested in sponsoring the event? Need help registering your team? Just get in touch and a member of the team will be happy to help.

Europe

USA East

USA West

Webinars

Dinners & Spotlights

R&D

R&D Boston

Medicinal Chemistry Strategy Meeting East Coast – Boston 2024

Medicinal Chemistry

Strategy Meeting East Coast USA 2025

<img class="lazy" decoding="async" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%201%201'%3E%3C/svg%3E" data-src="https://proventainternational.com/wp-content/uploads/2020/12/location.png" >Le Meridien Cambridge Boston

Fresh Medicinal Chemistry Insights

What makes our strategy meetings unique?

Roundtable Discussions

Unrivalled Networking

Personalised Agenda

Solutions to your Problems

Industry Researched Topics

Senior Decision Makers

Meet Our Facilitators

Aimee Usera

Benoit Moreau

Claire Elizabeth Smith

David Sherris

Diane Joseph-McCarthy

Dr. David Gosalvez

Dr. Tao Guo

Govinda Bhisetti

Hajnalka Hartl

Hua Xu

Huseyin Mehmet

Jennifer Petter

Kelly Barrett

Lee Fader

Lu Gong

Maneesh Pingle

Markus Haeberlein

Matthew Lucas

Michal Preminger

Nicolas Triballeau

Rich Heidebrecht

Rocky Goldsmith

Samantha Jeschonek Ph.D.

Shankar Venkatraman

Stefan Gross

Stephanie Oestreich

OUR AGENDA

See Which Topics Are Discussed at the Strategy Meeting

Breakfast & Registration

Opening Keynote Presentation

Roundtable ( Pharma/Biotech )

Roundtable Tracks

Refreshment Break

NETWORKING / 1-1 MEETINGS

NETWORKING / 1-1 MEETINGS

NETWORKING / 1-1 MEETINGS

Roundtable ( Solutions )

Roundtable Tracks

Sponsor

REVVITY SIGNALS

WUXI APPTEC

SAI LIFE SCIENCES

SAI LIFE SCIENCES

REVVITY SIGNALS

Roundtable ( Pharma/Biotech )

Roundtable Tracks

NETWORKING LUNCH

Networking / 1-1 Meetings

AFTERNOON KEYNOTE PRESENTATION

Augmented Discovery: How Revvity Signals’ AI/ML Amplifies Scientific Discovery

Roundtable ( Pharma/Biotech )

Roundtable Tracks

Afternoon Refreshment Break

Panel Discussion

Drinks & Canapes Reception

Reasons To Attend the Strategy Meeting

Our 2025 Sponsors

Lead Sponsor

Thought Leader

Co-Host Sponsor

Le Meridien Cambridge Boston